Platelet News and Research

RSS

Short-term use of selective COX-2 inhibitors may be safe for patients with cirrhosis of the liver

Short-term use of selective COX-2 inhibitors may be safe for patients with cirrhosis of the liver, according to a recent study that compared the effects of celecoxib, naproxen, and a placebo on cirrhotic patients in a double-blind randomized controlled study.

22 Feb 2005

Blood tests improve within two weeks of quitting smoking

Long-term smokers who quit may benefit from almost immediate improvements in blood platelet function, which could potentially reduce their risk of heart attacks or strokes caused by blood clots, according to a new study in the Feb. 15, 2005 issue of the Journal of the American College of Cardiology.

16 Feb 2005

Heart patients with gastrointestinal complications should use low doses of aspirin combined with drugs that treat stomach ulcers

Physicians are challenged in treating heart patients who may be at high-risk for gastrointestinal bleeding from aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). Factors that place patients at high-risk include a history of ulcers or gastrointestinal complications such as bleeding, increased age and congestive heart failure.

20 Jan 2005

Clopidogrel (Plavix®) responses appear normal in largest data set

Although individual patients respond differently to treatment with the anti-platelet medication clopidogrel (brand name Plavix®), those variations appear normal and may not indicate important differences in the effectiveness of treatment, according to a new study (PDF file) in the Jan. 18, 2005 issue of the Journal of the American College of Cardiology.

19 Jan 2005

Further evidence for the role of cyclooxygenases (COX) in heart-disease risk

In two articles, published in Circulation, researchers from the University of Pennsylvania School of Medicine provide further evidence for the role of cyclooxygenases (COX) in heart-disease risk.

17 Jan 2005

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Oncologists from USC/Norris Comprehensive Cancer Center are running tests on a new pancreatic cancer drug that targets the cancer from two directions.

13 Jan 2005

Potential new therapies for cancer and bleeding disorders

Lexicon Genetics announced today that it has advanced two of its drug discovery programs into preclinical development in preparation for investigational new drug (IND) applications.

10 Jan 2005

First assessment tool to evaluate Quebec Platelet Disorder (QPD)

Researchers at McMaster University have developed the first assessment tool of its kind for evaluating risks faced by Canadians suffering from a rare and often fatal bleeding disorder.

22 Dec 2004

New insight into anticoagulation therapies

Anticoagulation therapies, or treatments that reduce the amount of clotting factors in the blood, are quite common and used for a variety of reasons.

6 Dec 2004

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

Results from a clinical trial presented at the American Society of Hematology 46th Annual Meeting and Exposition (ASH) demonstrated that Zevalin (ibritumomab tiuxetan), administered as a first-line therapy, induced a 100 percent response rate in a small population of patients with low-grate follicular lymphoma (FL).

6 Dec 2004

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Modern research is delving deep into the human genome to find the answers to medical mysteries and, hopefully, cures for the most deadly diseases. According to four new studies presented during the 46th Annual Meeting of the American Society of Hematology

5 Dec 2004

Hydroxyurea plus aspirin best therapy in patients with essential thrombocythemia who are at high risk for vascular events

A new treatment for an incurable blood disorder proves a worse option for patients' health than an older treatment, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Telik, Inc. reported positive interim data from a Phase 2 trial of its Telintra (TLK199) drug candidate in myelodysplastic syndrome (MDS). The data were reported in two presentations at the annual meeting of the American Society of Hematology in San Diego.

5 Dec 2004

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

At the 46th Annual Meeting of the American Society of Hematology (ASH) preliminary data were presented from a phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia (MDS).

5 Dec 2004

New findings have implications for chronic use of COX-2 Inhibitors in pre-menopausal women

Heart disease is less pronounced in women than in men as humans age, but this difference narrows after menopause. Some studies have shown that estrogen slows heart disease in mouse models, but the mechanism is largely unknown.

18 Nov 2004

Concord grapes increase good cholesterol

Drinking Concord grape juice significantly increased HDL--the good cholesterol--and significantly lowered two markers of inflammation in people with stable coronary artery disease, according to results of a study presented in the November issue of the journal Arteriosclerosis, Thrombosis and Vascular Biology.

16 Nov 2004

Technology to determine a patient's response to aspirin therapy taken to prevent heart attacks

Herbal, nutritional supplements linked to side effects ranging from dry eye to retinal hemorrhages and transient visual loss

An estimated 42 percent of Americans use herbal medicines or nutritional supplements. Many people taking these products and their physicians are unaware of the adverse reactions they can cause.

13 Oct 2004

Platelet News and Research

Short-term use of selective COX-2 inhibitors may be safe for patients with cirrhosis of the liver

Blood tests improve within two weeks of quitting smoking

Heart patients with gastrointestinal complications should use low doses of aspirin combined with drugs that treat stomach ulcers

Clopidogrel (Plavix®) responses appear normal in largest data set

Further evidence for the role of cyclooxygenases (COX) in heart-disease risk

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Potential new therapies for cancer and bleeding disorders

First assessment tool to evaluate Quebec Platelet Disorder (QPD)

New insight into anticoagulation therapies

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Hydroxyurea plus aspirin best therapy in patients with essential thrombocythemia who are at high risk for vascular events

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

New findings have implications for chronic use of COX-2 Inhibitors in pre-menopausal women

Concord grapes increase good cholesterol

Technology to determine a patient's response to aspirin therapy taken to prevent heart attacks

The first test in humans of a bioartificial kidney

People who drank alcohol on a regular basis appeared to have less cardiovascular disease

Herbal, nutritional supplements linked to side effects ranging from dry eye to retinal hemorrhages and transient visual loss

Arrayed CRISPR Screening for Revolutionizing Target Discovery

Innovations in baculovirus–insect cell expression systems

Compound Management and its Crucial Role in Early Pharmaceutical Research

Latest News